CoreAge Rx advertises an online compounded semaglutide service with clinician review and delivery if a prescription is issued. The public product page gives a starting monthly price and describes an assessment process. It does not establish that every visitor is eligible or that the preparation is equivalent to an approved brand.
CoreAge is our paid featured partner and receives first placement in commercial comparisons. This review was checked September 23, 2026, and keeps that placement separate from the medical and regulatory questions a reader should resolve before considering the offer.
One thing to keep with you
The public offer is for compounded medication. Ask why an approved product cannot meet the specific medical need.
What the public offer includes
The semaglutide page advertises a starting price of $99 per month, no membership fees, an online questionnaire, clinician review, and delivery when treatment is prescribed. We reviewed the public description and the linked weight-management destination. We did not complete an intake, obtain an individualized quote, or receive medication.
Those boundaries matter because a functioning enrollment link is not evidence of the care a particular patient would receive. Our semaglutide introduction starts with the clinical questions that should come before a purchase decision, including the reason for treatment and the exact product proposed.
Checked with: CoreAge Rx: semaglutide offer · NIDDK: prescription weight-management medicines
Compounding is central to this review
A compounded semaglutide preparation is not FDA-approved and is not an FDA-approved generic of Wegovy or another brand. FDA says compounded GLP-1 drugs should be used only when a patient’s medical needs cannot be met by an approved drug. The clinical need and current requirements therefore deserve a specific explanation.
FDA resolved the semaglutide injection shortage in February 2025 and later clarified the relevant compounding policies. A provider page does not, on its own, establish that an individual prescription satisfies those requirements. Our compounding guide preserves that distinction instead of treating availability as unrestricted.
Checked with: FDA: concerns about unapproved GLP-1 products · FDA: compounding policy after supply stabilization · FDA: compounding questions and answers
Ask about the actual pharmacy and label
CoreAge provides a general explanation of its pharmacy network. Before accepting a prescription, confirm the pharmacy assigned to it and how to check its license. Ask for the formulation, concentration where relevant, storage requirements, beyond-use information, and the correct device instructions for the supplied product.
Do not borrow a syringe-unit number from another person’s vial or an online chart. FDA has reported dosing errors with compounded semaglutide, including hospitalizations. The safety guide explains why unclear instructions should lead to a pharmacist or prescriber conversation before use rather than an improvised conversion.
Checked with: CoreAge Rx: pharmacy network · FDA: checking online pharmacies · FDA: compounded semaglutide dosing errors
Put the starting price in a complete quote
The $99 starting figure is an advertised entry point, not a personally verified final invoice. Confirm whether the offered plan includes medication, supplies, shipping, assessment, follow-up, and any clinically required testing. Ask how renewal, cancellation, and refund conditions operate if a prescription is declined or the treatment plan changes.
Our cost article separates those questions, and the planner can add confirmed amounts. Price alone cannot establish clinical suitability, product quality, or comparative value when the products being compared have different approval status and care arrangements.
Checked with: CoreAge Rx: semaglutide offer · Ro: current program pricing · NovoCare: Wegovy pharmacy offer
Know who supports the next step
Ask which clinician will assess your medical history, how that clinician can treat you in your physical location, and how the service coordinates with existing care. Ongoing support should include a clear way to raise symptoms, prescription questions, and concerns about a shipment. Routine support access should not be understood as emergency coverage.
The public page’s service promises were not independently timed or tested in this review. Before enrollment, clarify response expectations and the plan for follow-up. Your treatment instructions should come from the responsible clinician and pharmacist, including what to do after a missed dose or an interruption.
Checked with: HHS: telehealth location and licensing · CoreAge Rx: semaglutide offer · Wegovy: current prescribing information
How to compare this with other routes to care
NovoCare’s Wegovy access route concerns approved branded products and manufacturer program terms. Ro’s model separates a clinical membership from medication charges. Those are useful comparisons precisely because they are different arrangements, not because we have established a single medical winner.
We have not audited a pharmacy, inspected a dispensed prescription, tested clinical outcomes, or completed a clinician review of this article. CoreAge’s position in the shortlist is disclosed paid placement. It should not be read as independent proof of superior safety, effectiveness, or individual suitability.
Checked with: NovoCare: Wegovy pharmacy offer · Ro: current program pricing · FDA: compounding questions and answers
Where we checked the facts
- CoreAge Rx: semaglutide offer
Commercial compounded-product offer, starting at $99/month when checked September 23, 2026. Not an FDA-approved generic or proof of comparative outcomes.
- NIDDK: prescription weight-management medicines
Background about clinical assessment and ongoing care; current product label controls newer formulation details.
- FDA: concerns about unapproved GLP-1 products
Current concerns include unapproved products, salt forms and adverse events. Compounding is not equivalent to generic approval.
- FDA: compounding policy after supply stabilization
Semaglutide injection shortage resolved in February 2025. Old shortage exemptions do not establish unrestricted present-day access.
- FDA: compounding questions and answers
Compounded drugs are not FDA-approved.
- CoreAge Rx: pharmacy network
Company explanation; the pharmacy for an actual prescription still needs confirmation.
- FDA: checking online pharmacies
Use official licensing and pharmacy checks; a review site is not a pharmacy auditor.
- FDA: compounded semaglutide dosing errors
Reports involving measurement and conversion errors, including hospitalizations; no universal syringe-unit conversion is appropriate.
- Ro: current program pricing
Membership and medication are separate charges. $39 introductory membership; $149 ongoing monthly or lower prepaid equivalents, subject to terms.
- NovoCare: Wegovy pharmacy offer
Manufacturer access and pricing terms checked September 23, 2026. Formulation, strength, eligibility and offer period affect cost.
- HHS: telehealth location and licensing
Clinician authorization and physical patient location must be verified for the actual service.
- Wegovy: current prescribing information
June 2026 label includes oral and injectable formulations with product-specific uses and instructions. Do not apply one formulation’s directions to another.
